Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2021 Publisher: Les Laboratoires Servier, 50, rue Carnot, 92284 Suresnes cedex, France
Natrilix SR 1.5 mg Tablets.
| Pharmaceutical Form |
|---|
|
Prolonged-release tablet. White, round, film-coated tablet. |
One prolonged-release film-coated tablet contains 1.5 mg indapamide.
Excipient with known effect: 124.5 mg lactose monohydrate.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Indapamide |
Indapamide is a sulfonamide derivative with an indole ring, pharmacologically related to thiazide diuretics, which acts by inhibiting the reabsorption of sodium in the cortical dilution segment. It increases the urinary excretion of sodium and chlorides and, to a lesser extent, the excretion of potassium and magnesium, thereby increasing urine output and having an antihypertensive action. |
| List of Excipients |
|---|
|
Tablet: Silica, colloidal anhydrous Film-coating: Glycerol |
10, 14, 15, 20, 30, 50, 60, 90, 100 tablets in blisters (PVC/aluminium).
Not all pack sizes may be marketed.
Les Laboratoires Servier, 50, rue Carnot, 92284 Suresnes cedex, France
PL 05815/0010
9th January 1996/25th February 2007 (MRP)
| Drug | Countries | |
|---|---|---|
| NATRILIX | Australia, Brazil, Germany, Ecuador, Finland, Hong Kong, Ireland, Italy, Malta, Mexico, Nigeria, Singapore, United Kingdom, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
